| 1.51 0.06 (4.14%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.08 | 1-year : | 2.51 |
| Resists | First : | 1.78 | Second : | 2.15 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.19 | Second : | 0.99 |
| MAs | MA(5) : | 1.77 |
MA(20) : | 1.51 |
| MA(100) : | 1.3 |
MA(250) : | 2.11 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 43.9 |
D(3) : | 64.9 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 4.04 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABVC ] has closed above bottom band by 41.3%. Bollinger Bands are 107% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.64 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.5 - 1.51 | 1.51 - 1.52 |
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Thu, 02 Jul 2026
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language - Stock Titan
Fri, 26 Jun 2026
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Fri, 26 Jun 2026
ABVC Should I Buy - Intellectia AI
Thu, 25 Jun 2026
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC) - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 18.5 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 273 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -87.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -3.88 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|